Here are three things to know:
1. The study authors performed a multicenter, double-blind, randomized controlled trial involving 3,424 patients. Patients underwent total hip or total knee arthroplasty.
2. All patients received 10 milligrams of oral rivaroxaban for five days postoperatively and then were randomly assigned to continue rivaroxaban or switch to aspirin.
3. Venous thromboembolism occurred in 0.64 percent of patients in the aspirin group and 0.70 percent of patients in the rivaroxaban group. Extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism in patients who underwent total hip or knee arthroplasty.
More articles on orthopedics:
Orthopedic surgeon to know: Dr. John Barker of the Rocky Mountain Spine Clinic
Orthopedic surgeon to know: Dr. Robert Arciero of UConn Health
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
